NurExone Biologic Inc.
NurExone Biologic Inc.
Your view on NRXBF
Overview
What the company does, where it operates, and who runs it.
About NurExone Biologic Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lior Shaltiel
- Headquarters
- 1 Adelaide Street East, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lior Shaltiel
- Headquarters
- 1 Adelaide Street East, Toronto, ON, CA
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for NurExone Biologic Inc., and the rating behind it. NRXBF last traded at $0.35; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for NurExone Biologic Inc.. Starting points for NurExone Biologic Inc.: EPS -$0.07, beta 0.39 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for NurExone Biologic Inc.. NurExone Biologic Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for NurExone Biologic Inc.. Trailing twelve-month EPS for NurExone Biologic Inc. stands at -$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for NurExone Biologic Inc.. NurExone Biologic Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
NurExone Biologic Inc. valued side by side against its closest peers. NurExone Biologic Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold NurExone Biologic Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by NurExone Biologic Inc. executives and directors. Shares of NurExone Biologic Inc. have traded between $0.30 and $0.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming NurExone Biologic Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming NurExone Biologic Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for NurExone Biologic Inc.. Coverage tracks NurExone Biologic Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.